Meenakshi Sambharia, MBBS

Meenakshi Sambharia practices at Southwest Kidney Institute, PLC in Tempe, Arizona.

Meenakshi Sambharia's NPI, 1346623055, was assigned on June 30, 2015. Meenakshi Sambharia holds Iowa license MD-47104.

Meenakshi Sambharia's primary practice is Southwest Kidney Institute, PLC, at 2149 E Warner Rd, Tempe, AZ 85284 in Maricopa County. The practice phone is (480) 969-8714.

Meenakshi Sambharia's primary practice is Southwest Kidney Institute, PLC in Tempe, Arizona. Meenakshi Sambharia is also affiliated with Dignity Health Chandler Regional Medical Center. The medical group on file is Southwest Kidney Institute. Dmand AI also links Meenakshi Sambharia to 4 more hospitals, 2 group practices and clinics, 1 dialysis center and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Meenakshi Sambharia practices, 8 sites in all. Vendor and product names are available with a free account.

Nephrology is Meenakshi Sambharia's primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Dmand AI has Meenakshi Sambharia's licenses on file in 2 states: Iowa and Pennsylvania.

CMS data shows 833 Medicare services from Meenakshi Sambharia across 12 procedure codes in 2024, for 251 Medicare patients. Medicare paid $79,332 for them.

CMS counts 251 Medicare patients who saw Meenakshi Sambharia in 2024. The largest group is 65 to 74, with 94 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. 24% are also on Medicaid. Their average risk score is 4.93, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Meenakshi Sambharia's median patient age at 67, with 48% women.

In 2024, Meenakshi Sambharia wrote 412 Medicare Part D claims for 84 patients. 88% of them were for generic drugs. CMS names the drug for 245 of them, across 10 drugs with 11 or more claims each, at $42,110 in total drug cost. In 2023, CMS named 197 claims across 8 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 80 out of 100 for Meenakshi Sambharia for performance year 2024, reported as part of a group. Meenakshi Sambharia accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 11 papers to Meenakshi Sambharia, published from 2022 to 2025. 2023 was the busiest year, with 4. The most frequent topics are Hypertension, Acute Kidney Injury and Blood Pressure. Meenakshi Sambharia has published most often in PLoS One. Meenakshi Sambharia's most frequent co-authors are Masaaki Yamada, MD, Lisa M. Antes, MD and Mony Fraer, MD.

CMS Open Payments shows 33 general payments to Meenakshi Sambharia from 22 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 100% of the total. Bristol-Myers Squibb Company paid the most, $292.